| 21.86 1.21 (5.86%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 27.39 | 1-year : | 29.95 |
| Resists | First : | 23.45 | Second : | 25.64 |
| Pivot price | 22.73 |
|||
| Supports | First : | 19.9 | Second : | 16.55 |
| MAs | MA(5) : | 22.35 |
MA(20) : | 22.68 |
| MA(100) : | 19.61  |
MA(250) : | 10.84 |
|
| MACD | MACD : | -0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 19.1 |
D(3) : | 30.3 |
| RSI | RSI(14): 45.7 |
|||
| 52-week | High : | 25.77 | Low : | 2 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ LENZ ] has closed above bottom band by 31.2%. Bollinger Bands are 3.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 22.32 - 22.46 | 22.46 - 22.58 |
| Low: | 19.76 - 19.9 | 19.9 - 20.04 |
| Close: | 21.62 - 21.85 | 21.85 - 22.07 |
LENZ Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Fri, 13 Sep 2024
LENZ Therapeutics (NASDAQ:LENZ) Stock Price Up 7.8% - MarketBeat
Thu, 12 Sep 2024
LENZ Therapeutics Insiders Up US$178k On US$551.1k Investment - Yahoo Finance UK
Fri, 30 Aug 2024
LENZ Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Fri, 30 Aug 2024
Lenz Therapeutics: Upcoming PDUFA, Strong Data, Some Risks (NASDAQ:LENZ) - Seeking Alpha
Mon, 15 Jul 2024
LENZ Therapeutics Secures $30 Million Through Private Share Sale - TipRanks
Tue, 11 Jun 2024
LENZ Therapeutics Merges With Graphite Bio - San Diego Business Journal
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 27 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 5.2 (%) |
| Held by Institutions | 93.1 (%) |
| Shares Short | 2,100 (K) |
| Shares Short P.Month | 2,000 (K) |
| EPS | -2.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.46 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.74 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -74 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -7.98 |
| PEG Ratio | -0.4 |
| Price to Book value | 2.93 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.14 |
| Dividend | 7.21 |
| Forward Dividend | 0 |
| Dividend Yield | 32.9% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|